Related Experiment Video
Updated: Jun 9, 2026
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients
Manpreet K Chadha1, Marwan Fakih, Josephia Muindi
1Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.
Background:
Epidemiologic data suggest that there is an association between vitamin D deficiency and influenza infection. We conducted a prospective influenza vaccination study to determine the influence of vitamin D status on serological response to influenza vaccine in prostate cancer (CaP) patients.
Methods:
During the 2006-2007 influenza season, CaP patients treated at Roswell Park Cancer Institute were offered vaccination with the trivalent influenza vaccine (Fluzone®, 2006-2007) and sera collected for hemagglutination inhibition (HI) assay titers before and 3 months after vaccination. Response to vaccination was defined as ≥1:40 titer ratio or a fourfold increase in titer at 3 months, against any of the three strains. Serum 25-hydroxyvitamin D (25-D₃) levels were measured using DiaSorin ¹²⁵I radioimmunoassay kits.
Results:
Thirty-five patients with CaP participated in the study. Median baseline 25-D₃ level was 44.88 ng/ml (range: 9.16-71.98 ng/ml) Serological response against any of the three strains was noted in 80%. There was a significant effect of baseline 25-D3 level when tested as a continuous variable in relation to serological response (P = 0.0446). All patients in the upper quartile of 25-D3 level responded by mounting a serological response (P = 0.0344). None of the other baseline variables (age, race, chemotherapy status, or white cell count) had an effect on serological response.
Conclusions:
In this study in CaP patients, a replete vitamin D status was associated with more frequent serological response to influenza vaccine.
